Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, ...
https://www.google.com/url?rct=j&sa=t&url=https://www.etfdailynews.com/2022/06/20/head-to-head-comparison-fortress-biotech-nasdaqfbio-xbiotech-nasdaqxbit/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw3mIZ-p8gte84zJRq1tX-XH
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.